India’s Healthcare Opportunity, Part II.

In our earlier article, India’s Healthcare Decade: Why Demand May Outpace Supply for Years,(https://www.pwm-india.com/post/india-s-healthcare-decade-why-demand-may-outpace-supply-for-years), we laid out a structural case for the growth in India’s healthcare sector. Rising incomes, increasing insurance penetration, an ageing population, a growing burden of chronic diseases, and a persistent shortage of quality healthcare infrastructure, all pointing towards a long runway for demand across the healthcare value chain. That thesis remains intact; however a compelling industry story may not always automatically translate into a compelling investment. As expectations rise and capital follows opportunity, the question for investors becomes more demanding: How much of this growth is already reflected in the valuations? Which businesses can convert rising demand into sustainable earnings and subsequently deliver attractive returns on capital? And where could competition, regulation, execution or changing industry economics challenge the broader healthcare narrative?

In Part II, we revisit the healthcare opportunity from the other side of the argument—stress-testing the thesis and examining the risks, valuations and industry dynamics that could determine whether strong structural growth ultimately translates into strong investment returns.

ICRA estimates that 18 major hospital chains could add more than 34,000 beds between FY26 and FY30, expanding their existing capacity by around 50%, with cumulative capex of ~₹40,000 crore. Yet these additions would represent only ~2.5% of India’s existing private hospital bed capacity, underscoring both the scale of the opportunity and the fragmented nature of the market. This expansion cycle also brings the investment challenge into sharper focus. As the chart below illustrates, higher capex intensity does not necessarily translate into the market granting a higher EV/EBITDA multiple. Despite broadly similar growth ambitions amongst the top chains, valuations vary meaningfully, suggesting that the market is looking beyond the quantum of capital being deployed. What matters increasingly is the quality of that deployment—how quickly new capacity reaches optimal occupancy, how effectively margins scale, and whether incremental capital generates attractive returns. In other words, as the sector moves from a demand-led growth story to a capacity-led expansion phase, execution and capital efficiency are likely to become increasingly important drivers of shareholder returns.

For a hospital chain, the critical variables are how quickly new beds ramp up, whether occupancy and ARPOB (Average Revenue Per Occupied Bed) reach sustainable levels, and what return is ultimately generated on the capital deployed. Capex creates the potential for growth; execution determines whether that growth creates economic value. From the graph below, a second pattern emerges when valuation is viewed against the scale of the hospital platform. Larger chains tend to command higher multiples, but scale alone does not explain the dispersion. The premium appears more meaningful when a company has demonstrated an ability to build capacity, ramp occupancy and maintain healthy margins across an expanding network.

Note: EV = Market Cap + Debt – Cash, EBITDA is calculated excluding Other Income.

This distinction matters because investors are effectively valuing not only the earnings of the existing bed base, but also the credibility of replicating its economics across future capacity. In that sense, the market is placing a value on the repeatability of the hospital model - not merely on the size of the current asset base. The data below provides a useful benchmark for assessing the operating economics of hospital chains as they expand capacity. It helps distinguish between companies merely adding beds and those converting expansion into stronger utilisation, pricing and revenue growth.

1. Occupancy of ~64–65% is the sector benchmark. Hospitals sustaining occupancy around this level are broadly in line with the industry, while materially higher occupancy can indicate stronger demand and asset utilisation. Persistently lower occupancy—particularly in mature hospitals—requires closer scrutiny.

2. Revenue is expected to grow ~14–15% annually. This provides a useful benchmark for judging whether capacity additions are translating into growth. Companies consistently growing faster than this, without sacrificing margins or returns, are likely gaining market share or benefiting from superior execution.

3. ARPOB is rising by ~6–9% annually. This reflects improving case mix, greater contribution from high-end specialties and pricing. Operators delivering ARPOB growth above the industry trend while maintaining volumes are particularly attractive; weak ARPOB growth may indicate an inferior specialty mix or limited pricing power.

4. ALOS(Average length of stay) is declining towards ~3.6 days. Shorter stays generally indicate better throughput and allow hospitals to generate more revenue from the same bed base. Operators reducing ALOS while maintaining clinical outcomes and occupancy are therefore using their assets more efficiently.

   
   

Taken together, these metrics provide a practical benchmark for evaluating hospital economics: operators that consistently track industry trends can be considered healthy. The chart below brings the two central drivers of hospital revenue—occupancy and ARPOB—into a single framework. Hospitals with high occupancy but relatively lower ARPOB represent a volume-led model, where utilisation is the primary driver of revenue. At the other end, hospitals combining high occupancy with higher ARPOB reflect stronger realisations supported by case mix, specialty mix and pricing.

The distinction is important because adding beds does not, by itself, create earnings. A new bed contributes meaningfully only when it reaches sustainable occupancy while maintaining an attractive ARPOB. Growth can therefore come from better utilisation of the existing asset base, higher realisations, or both. The strongest hospital economics emerge when these levers reinforce each other.

Hospital profitability has strengthened materially over the past few years, with EBITDA margins rising from 11.5% in FY19 to 20.6% in FY25 on average. Despite the ongoing capacity-expansion cycle and rising capital intensity, margins are expected to remain resilient at around 20–21% through FY27. The cost structure is also relatively diversified, with material costs accounting for ~22–24% of revenue, while doctor fees, employee costs and other expenses each account for roughly 16–19%.

However, stable industry-level margins can mask significant differences in the economics of individual hospitals, particularly during periods of rapid expansion. New facilities typically begin with lower occupancy and carry substantial fixed costs during the ramp-up period, which can weigh on near-term profitability. The key differentiator will therefore be how quickly operators can ramp up new capacity, improve utilisation and generate sufficient ARPOB to absorb these costs. Companies that can expand while sustaining margins around or above the industry benchmark are likely to demonstrate superior capital efficiency, while those experiencing prolonged margin dilution may indicate weaker execution or less attractive economics.

Regulation: a key variable to monitor.

Regulatory risk for private hospitals has historically been relatively contained, particularly on hospital services, allowing operators meaningful flexibility in pricing, case mix and service mix. However, this could gradually change as policymakers place greater emphasis on healthcare affordability. While India does not currently have a nationwide cap on private hospital service charges, the Centre is working within the existing Clinical Establishments Framework, under which procedure and service charges could eventually be brought within government-determined ranges. At the same time, proposals around hospital room rents and greater scrutiny of medical consumables point towards a potentially broader regulatory footprint.

The composition of healthcare costs help explain why medicine pricing has become an important area of scrutiny. Medical goods account for over two-thirds of the medical inflation basket, with medicines being the largest component, while hospital services have historically remained relatively less regulated. Within hospital bills, medicines also represent a meaningful component of inpatient costs, although their share varies materially between inpatient and outpatient care. This creates an important distinction for investors: regulation of medicine prices may not directly translate into an equivalent impact on hospital profitability, but it can affect the economics of pharmacy-related revenues and the overall patient bill.

Recent developments suggest that this issue is moving closer to the centre of the regulatory debate. In September 2026, the Supreme Court questioned steep mark-ups on certain cancer medicines sold through hospitals and asked the Centre to examine whether a uniform 16% margin could be considered across medicines. The Court also sought scrutiny of allegations that some hospitals require patients to purchase medicines through their own or designated pharmacies. The development highlights the possibility of greater scrutiny of medicine pricing and hospital pharmacy practices.

Taken together, the regulatory landscape is evolving across several fronts: NPPA price controls on essential medicines, existing price ceilings on certain medical devices such as coronary stents, scrutiny of procurement-to-MRP spreads in hospital consumables, the continuing debate around procedure and service-rate ranges under the Clinical Establishments framework, and the August 2026 Parliamentary Standing Committee recommendation on benchmarking basic room charges in large metropolitan hospitals. Several of these remain proposals, recommendations or evolving frameworks rather than binding nationwide price caps. For investors, therefore, the key variable is not regulation in isolation, but the proportion of hospital revenue exposed to regulated or externally determined pricing—and the ability of operators to preserve margins as that exposure potentially increases.

The investment equation is therefore that new capacity must translate into occupancy; occupancy into revenue; and revenue into sustainable cash flows and incremental ROCE. At the same time, the growing focus on healthcare affordability could gradually increase regulatory oversight which investors need to watch out for. While current valuations embed substantial expectations of continued growth, the opportunity, therefore, lies not merely in identifying businesses exposed to India’s healthcare demand, but in distinguishing those that can price their services effectively, allocate capital with discipline, scale without diluting returns, and consistently replicate the economics of their successful hospital branches.

Kind Regards, 

Research Desk, 

Team PWM.